- September 16, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Atropine PO,Atreza,Saltropine
Synonyms :
atropine
Class :
Antispasmodic agents, Anticholinergic agents,Antidote
Brand Name :
Atropine PO,Atreza,Saltropine
Synonyms :
atropine
Class :
Antispasmodic agents, Anticholinergic agents,Antidote
Dosage Forms & Strengths
Tablet
0.4mg
Indicated for Bradyarrhythmia:
0.4 to 1mg intravenous every 2 hours as needed
0.4mg to 0.6mg intravenous, subcutaneous, or intramuscularly
Dosage Forms & Strengths
Tablet
0.4mg
Indicated for Bradyarrhythmia:
0.02mg/kg/dose intravenous, which can repeat every 5 minutes
Refer adult dosing
may increase the constipating effect of anticholinergic agents
may decrease the therapeutic effect of anticholinergic agents
may diminish the excretion rate of amantadine
may increase the anticholinergic effect of anticholinergic agents
may increase the constipating effect of anticholinergic agents
may increase the anticholinergic effect of anticholinergic agents
may decrease the diagnostic effect of atropine
may increase the anticholinergic effect of anticholinergic agents
may increase the ulcerogenic effect of anticholinergic agents
may increase the ulcerogenic effect of anticholinergic agents
may increase the anticholinergic effect of anticholinergic agents
may increase the anticholinergic effect of anticholinergic agents
may increase the anticholinergic effect of anticholinergic agents
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of anticholinergic agents
may increase the anticholinergic effect of anticholinergic agents
may increase the anticholinergic effect of anticholinergic agents
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of anticholinergic agents
may increase the serum concentration of anticholinergic agents
may increase the serum concentration of anticholinergic agents
may increase the serum concentration of anticholinergic agents
may increase the serum concentration of anticholinergic agents
may increase the toxic effect of anticholinergic agents
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the therapeutic effect
may increase the tachycardic effect
may increase the tachycardic effect
May enhance the tachycardic effect
May enhance the tachycardic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may enhance the risk or severity of hypertension when combined
may decrease the cholinergic effect of cholinergic agents
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
reduce the therapeutic effect
reduce the therapeutic effect
reduce the therapeutic effect
reduce the therapeutic effect
reduce the therapeutic effect
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
Actions and Spectrum:
Frequency not defined
Coma
Delirium
Drowsiness
Headache
Nervousness
Flushing
Tachycardia
Ataxia
Confusion
Dizziness
Hallucinations
Insomnia
Arrhythmia
Hypotension
Palpitation
Pulmonary edema
Constipation
Bloating
Dyspnea
Delayed gastric emptying
Loss of taste
Vomiting
Xerostomia
Fever
Urticaria
Urinary hesitancy and retention
Anaphylaxis
Blurred vision
Ocular pressure increased
Paralytic ileus
Nasal dryness
Rash
Scarlantiniform rash
Angle-closure glaucoma
Dry eyes
Nausea
Anhidrosis
Contraindications/caution:
Contraindications:
Caution:
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology: